Résumé
Objective To explore the clinical significance of detecting CD4+ T cell ATP and subgroup count in patients with liver cancer recurrence after liver transplantation. Methods From November 2015 to November 2018, 84 patients with primary liver cancer underwent orthotopic liver transplantation in Shanghai Changzheng Hospital were selected and then divided into recurrence group (n=42) and non-recurrence group (n=42) according to whether the tumor recurred. Peripheral blood samples were collected on the day of diagnosis and 1, 3, 6 months after recurrence. ATP content in CD4+ T lymphocytes was detected using ImmuKnowTM immune cell function assay kit, subgroup counts were detected using IOTest. Results ATP content of CD4+ T lymphocytes in patients with liver cancer recurrence after liver transplantation was significantly lower than that in patients without recurrence at the day of diagnosis of recurrence, and 1, 3, 6 months after recurrence (P<0.05). The count of CD4+ T lymphocyte subsets in the reoccurence group had no significant change within 1 month after recurrence compared with the non-recurrence group. When the recurrence time continued to extend to 3 months and 6 months, there was a significant downward trend in both the two groups. Conclusion The immune status of patients with liver cancer recurrence after liver transplantation decreased gradually with the passage of time. Monitoring the ATP content and subgroup count of CD4+ T cells can better evaluate the immune status of patients with liver cancer recurrence after liver transplantation, being of certain practical value in formulating individualized programs.